SEC Form 4 · accession 0001144204-18-014761
Edesa Biotech, Inc. · EDSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel E. Morse
Director
Period of report
Feb 22, 2018
Accepted (ET)
Mar 14, 2018 · 8:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001540159
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par value | Feb 22, 2018 | S | 7,800 | $0.784 | D | 28,866 | I | Joint Account with Spouse |
| Common shares, without par value | Feb 26, 2018 | S | 7,000 | $0.79 | D | 21,866 | I | Joint Account with Spouse |
| Common shares, without par value | Feb 28, 2018 | S | 7,000 | $0.79 | D | 14,866 | I | Joint Account with Spouse |
| Common shares, without par value | Mar 9, 2018 | S | 7,000 | $0.805 | D | 7,866 | I | Joint Account with Spouse |
| Common shares, without par value | Mar 12, 2018 | S | 3,500 | $0.797 | D | 4,366 | I | Joint Account with Spouse |
| Common Shares, without par value | holding | — | — | — | 194,523 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $0.84 | Mar 12, 2018 | A | 2,500 | A | — | Mar 12, 2025 | Common Shares | 2,500 | 2,500 | D |
Explanation of responses
- F1Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019.